- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Insights from the TROPION-Lung05 Trial at ASCO 2024
Jason Porter, MD, analyzes the TROPION-Lung05 trial investigating Dato-DXd in non-small cell lung cancer patients with brain metastases, emphasizing crucial insights from this pivotal study.
EP: 1.Expert Insights on NSCLC: Unmet Needs and Innovations from ASCO 2024
EP: 2.ASCO 2024: Key Findings of the LAURA Trial on7:19 Osimertinib for EGFR-Mutated NSCLC
EP: 3.Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024
EP: 4.Insights from the TROPION-Lung05 Trial at ASCO 2024
EP: 5.Long-Term Follow-Up from CheckMate 9LA at ASCO 2024
EP: 6.ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions
Video content above is prompted by the following questions:
- Discuss the data that was presented at the ASCO 2024 on intracranial overall response rate in the TROPION-Lung05 trial with Dato-DXd in patients with brain metastasis from NSCLC.
- What are your key takeaways from this study and how will this impact the treatment of patients with brain metastasis from NSCLC?
FDA Approves Companion Diagnostic for Tepotinib in MET Exon 14 mNSCLC
November 18th 2024The FDA approved the FoundationOne Liquid CDx to identify patients with metastatic non–small cell lung cancer (mNSCLC) with MET exon 14 skipping alterations who may be eligible for tepotinib (Tepmetko; EMD Serono).
Read More
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Expanding Access to NSCLC Innovations: Challenges and Opportunities
October 18th 2024The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and improving treatment access, in particular for immunotherapy and targeted treatments.
Read More
